MedTrace Logo

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

NCT06846268 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-25

No results posted yet for this study

Summary

This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.

Conditions

  • Locally Advanced Colorectal Cancer

Interventions

DRUG

ADG126

Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).

DRUG

Pembrolizumab

Administered via intravenous infusion on Day 1 and Day 22.

Sponsors & Collaborators

  • Adagene Inc

    collaborator INDUSTRY

  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Wei Peng Yong, MD · National University Hospital, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-14
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06846268 on ClinicalTrials.gov